Scott Braunstein - Jan 18, 2024 Form 4 Insider Report for MARINUS PHARMACEUTICALS, INC. (MRNS)

Role: CHAIRMAN AND CEO, Director
Signature: /s/ Debra A. Mohollen, Attorney-in-Fact
Stock symbol: MRNS
Transactions as of: Jan 18, 2024
Transactions value $: $0
Form type: 4
Date filed: 1/19/2024, 04:18 PM
Previous filing: Aug 8, 2023
Next filing: Feb 21, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MRNS	Common Stock	Award	$0	+74.6K	+46.4%	$0.00	235K	Jan 18, 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MRNS	Stock Option (Right to Buy)	Award	$0	+336K		$0.00	336K	Jan 18, 2024	Common Stock	336K	$9.74	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the grant of restricted stock units (RSUs). The RSUs vest in three equal installments, with the first installment vesting on February 15, 2025, the second installment vesting on February 15, 2026, and the third installment vesting on February 15, 2027, subject to the reporting person's continued service with Marinus Pharmaceuticals, Inc. (the Issuer). Each RSU represents the right to receive one share of common stock of the Issuer.
F2	The option vests and becomes exercisable in 36 equal monthly installments beginning on February 18, 2024, subject to the reporting person's continued service with the Issuer.

Content

Represents the grant of restricted stock units (RSUs). The RSUs vest in three equal installments, with the first installment vesting on February 15, 2025, the second installment vesting on February 15, 2026, and the third installment vesting on February 15, 2027, subject to the reporting person's continued service with Marinus Pharmaceuticals, Inc. (the Issuer). Each RSU represents the right to receive one share of common stock of the Issuer.

The option vests and becomes exercisable in 36 equal monthly installments beginning on February 18, 2024, subject to the reporting person's continued service with the Issuer.